IL2 and neoplasm: Several dose-limited protein therapies are currently in trials as intratumoral therapies: OX40 agonist antibody (NCT03831295), CD137 agonist antibody (NCT03792724), bispecific antibody MDX-447 (NCT00005813), anti-PD-1 and anti-CTLA-4 antibodies (NCT03058289), and tumor-targeted IL-2 and TNFα (NCT04362722).